Journal
CANCER RESEARCH
Volume 70, Issue 23, Pages 9538-9543Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-1003
Keywords
-
Categories
Funding
- INSERM
- La Ligue contre le cancer, Fondation de France
- Fondation pour la Recherche Medicale
- Institut National du Cancer
- European Union
- Cancerople Ile-de-France
- Fondation Gustave Roussy
- AICR
Ask authors/readers for more resources
Current cancer management aims to integrate molecular signatures into the design of personalized therapies. Recent advances in omics'' done on tumor specimens have led to the identification of factors that either recognize cancers of dismal prognosis or pinpoint druggable'' signaling pathways, which can be interrupted by targeted therapies. However, accumulating evidence underscores the biological and clinical significance of immune predictors in several compartments (blood, serum, tumor) in a variety of malignancies. An additional aspect that has been overlooked is the bidirectional, tumor-host interaction during therapeutic intervention, suggesting that dynamic molecular, biochemical, and metabolic signatures should be developed in the future. We review immune parameters of prognostic or predictive value during cancer therapy, and highlight existing descriptive-prognostic'' and functional-therapeutic'' molecular signatures, with the hindsight of designing appropriate compensatory therapies. Cancer Res; 70(23); 9538-43. (C) 2010 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available